| 05/06 | Celyad Oncology SA Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 03/25 | TRANSCRIPT : Celyad Oncology SA, 2021 Earnings Call, Mar 25, 2022 | CI |
| 03/25 | CELYAD ONCOLOGY : Reports Full Year 2021 Financial Results and Recent Business Highlights .. | PU |
| 03/25 | CELYAD ONCOLOGY : Letter to Shareholders – March 2022 | PU |
| 03/24 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
| 03/24 | Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights | AQ |
| 03/17 | CELYAD ONCOLOGY : to Announce Full Year 2021 Financial Results and Host Conference Call | PU |
| 03/02 | Celyad Says FDA Places Early-Stage Colorectal Cancer Trial on Clinical Hold | MT |
| 03/02 | Celyad Oncology Slips 6% on US FDA's Clinical Hold on Colorectal Cancer Treatment Trial | MT |
| 03/02 | Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial | AQ |
| 03/02 | Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial | CI |
| 03/01 | GLOBAL MARKETS LIVE : Bayer, HP, Shell, Toshiba, Citigroup... | |
| 02/28 | HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday .. | MT |
| 02/28 | CELYAD ONCOLOGY : Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial - Form 6-K | PU |
| 02/28 | Celyad Pauses Early-Stage Colorectal Cancer Trial Amid Safety Issues | MT |
| 02/28 | Celyad Oncology SA Announces Voluntary Pause of CYAD-101-002 Phase 1B Trial | CI |
| 02/28 | Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial | AQ |
| 02/02 | CELYAD ONCOLOGY : Summary Note – Listing Prospectus | PU |
| 02/02 | CELYAD ONCOLOGY : Securities Note | PU |
| 01/31 | Celyad Oncology Announces February 2022 Conference Schedule | AQ |
| 01/12 | CELYAD ONCOLOGY : Provides Outlook for 2022 - Form 6-K | PU |
| 01/12 | Celyad Oncology SA Announces Program Update and Anticipated Milestones for 2022 | CI |
| 01/11 | Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Ra.. | MT |
| 2021 | Celyad Oncology Announces January 2022 Conference Schedule | AQ |
| 2021 | Transparency notification received from Tolefi SA and related persons (Article 14 §1 of.. | AQ |
| 2021 | Celyad Oncology - Transparency notification received from Fortress Investment Group LLC | AQ |
| 2021 | Celyad Oncology Doses First Patient in Trial of Colorectal Cancer Treatment | MT |
| 2021 | Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial | AQ |
| 2021 | Celyad Oncology SA Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial | CI |
| 2021 | CELYAD ONCOLOGY : Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Me.. | PU |
| 2021 | CELYAD ONCOLOGY : Transparency Notification Fortress Investment Group LLC | PU |
| 2021 | TRANSCRIPT : Celyad Oncology SA - Special Call | CI |
| 2021 | Celyad Oncology SA Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annua.. | CI |
| 2021 | GLOBAL MARKETS LIVE : Apple, Volkswagen, Uber, Rolls-Royce, Gamestop... | |
| 2021 | Celyad Oncology Concludes $33 Million Private Placement | MT |
| 2021 | Celyad Oncology Closes $32.5 Million Share Sale to Fortress Investment Affiliate | MT |
| 2021 | CELYAD ONCOLOGY : Announces Closing of $32.5 Million Private Placement with Fortress Inves.. | PU |
| 2021 | Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Inve.. | AQ |
| 2021 | Celyad Oncology SA announced that it has received €28.73 million in funding from F.. | CI |
| 2021 | Celyad Oncology Announces $32.5 Million Private Placement with Fortress | AQ |
| 2021 | Health Care Stocks Drifting Lower Ahead of Weekend | MT |
| 2021 | Health Care Stocks Inching Lower But Outperform Most Industry Sectors | MT |
| 2021 | Top Midday Gainers | MT |
| 2021 | CELYAD ONCOLOGY : Announces $32.5 Million Private Placement with Fortress Investment Group.. | PU |
| 2021 | Wall Street Set for Narrow Gains, US Unemployment Rate Falls in November | MT |
| 2021 | Health Care Stocks Rise in Premarket Friday | MT |
| 2021 | Top Premarket Gainers | MT |
| 2021 | Celyad Oncology Shares Surge on $32.5 Million Placement | DJ |
| 2021 | Celyad Secures $32.5 Million Equity Investment From Fortress | MT |
| 2021 | Celyad Oncology to Raise $33 Million by Issuing 29% Stake to Fortress | MT |
| 2021 | Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Grou.. | AQ |
| 2021 | Celyad Oncology SA announced that it expects to receive €28.73 million in funding .. | CI |
| 2021 | CELYAD ONCOLOGY : Coordinated Articles of Association | PU |
| 2021 | Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highl.. | PU |
| 2021 | Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highl.. | AQ |
| 2021 | Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highl.. | CI |
| 2021 | GLOBAL MARKETS LIVE : Daimler, Delivery Hero, Foxconn, China Evergrande, Kraft Heinz... | |
| 2021 | Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business High.. | AQ |
| 2021 | Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business High.. | PU |
| 2021 | Celyad Oncology Announces November 2021 Conference Schedule | PU |
| 2021 | CELYAD : Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society f.. | AQ |
| 2021 | CELYAD ONCOLOGY SA(ENXTBR : CYAD) dropped from S&P Global BMI Index | CI |
| 2021 | CELYAD ONCOLOGY : Supplement n°1 to the Registration Document | PU |
| 2021 | CELYAD ONCOLOGY : announces September 2021 Conference Schedule | PU |
| 2021 | CELYAD : Oncology Announces September 2021 Conferences Schedule | AQ |
| 2021 | CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Ma.. | MT |
| 2021 | TRANSCRIPT : Celyad Oncology SA, H1 2021 Earnings Call, Aug 05, 2021 | CI |
| 2021 | CELYAD ONCOLOGY : Reports First Half 2021 Financial Results and Recent Business Highlights.. | PU |
| 2021 | CELYAD : Oncology Reports First Half 2021 Financial Results and Recent Business Highlights | AQ |
| 2021 | Celyad Oncology Sa Reports Earnings Results for the Half Year Ended June 30, 2021 | CI |
| 2021 | CELYAD : Oncology to Announce First Half 2021 Financial Results and Host Conference Call | AQ |
| 2021 | CELYAD ONCOLOGY : Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based.. | BU |
| 2021 | Celyad Oncology SA Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-b.. | CI |
| 2021 | TRANSCRIPT : Celyad Oncology SA - Special Call | CI |
| 2021 | CELYAD : Oncology to Host Virtual Research & Development Webinar on July 20th | AQ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
